The Privileged Heterocyclic Primary Amine Building Block for GABA A Receptor Modulators, GSK3 Kinase Inhibitors, and HIV-1 Protease Inhibitors: 4-Aminoisoxazole (Isoxazol-4-amine, CAS# 108511-97-3)

4-Aminoisoxazole (CAS# 108511-97-3), also known as isoxazol-4-amine, 1,2-oxazol-4-amine, or isoxazole-4-amine, is a heterocyclic primary amine with the molecular formula C₃H₄N₂O and a molecular weight of 84.08 g/mol. Its molecular structure features a five-membered isoxazole ring bearing a primary amino group at the 4-position. This specific substitution pattern—an amino group positioned at C4 of the isoxazole ring—confers unique electronic properties that distinguish it from its 3-amino and 5-amino positional isomers, making it a privileged scaffold in medicinal chemistry and pharmaceutical development.

4-Aminoisoxazole is typically supplied as a brown solid (hydrochloride salt) or as a free base with a melting point of 130–135°C with decomposition. The hydrochloride salt form (CAS 108511-98-4) is also commercially available as a brown solid with a molecular weight of 120.54 g/mol. The compound is soluble in polar organic solvents and is typically supplied at ≥95% to ≥97% purity. It should be stored in a cool, dark place under inert atmosphere to prevent degradation. Under GHS, it is classified with the signal word “Warning” (H315, H319, H335) and requires standard laboratory safety precautions during handling.

4-Aminoisoxazole is a strategically important privileged heterocyclic primary amine building block that serves as a critical intermediate in the synthesis of GABA A receptor modulators, glycogen synthase kinase 3 (GSK3) inhibitors, HIV-1 protease inhibitors, and other bioactive molecules. Its unique combination of a basic primary amino group, an electron-rich isoxazole ring, and the ability to participate in diverse chemical transformations—including nucleophilic substitution, acylation, reductive amination, and cyclization—positions it as an indispensable tool in modern medicinal chemistry and drug discovery. Based on its chemical characteristics and pharmaceutical significance, this article systematically analyzes the key properties, core application areas, global market structure, regulatory landscape, and future outlook of this strategically important heterocyclic building block.

Core Application Fields and Demand

Market demand for 4-aminoisoxazole (CAS# 108511-97-3) is concentrated in four primary sectors: pharmaceutical R&D and drug discovery (approximately 50–55% of global consumption), medicinal chemistry and chemical biology research (approximately 20–25%), agrochemical development (approximately 15–20%), and specialty chemical synthesis and materials science (approximately 10–15%). Its privileged isoxazole scaffold and versatile primary amine functionality serve as the core drivers of sustained demand growth.

In pharmaceutical R&D and drug discovery, 4-aminoisoxazole is a cornerstone building block for the synthesis of therapeutic agents targeting neurological and metabolic disorders. The compound is specifically used in the synthesis of GABA A receptor modulators, making it a valuable lead for epilepsy, anxiety, and sleep disorder research. GABA A receptors are the primary inhibitory neurotransmitter receptors in the central nervous system, and modulators of these receptors are clinically important for treating seizure disorders, anxiety, and insomnia. 4-Aminoisoxazole serves as a versatile intermediate in the synthesis of kinase inhibitors, including GSK3 inhibitors (Ki 0.001–10,000 nM range), and is a validated starting material for the preparation of glycogen synthase kinase 3 (GSK3) inhibitors from 5-methyl-4-aminoisoxazole precursors. GSK3 is a serine/threonine kinase implicated in numerous diseases including diabetes, Alzheimer’s disease, and bipolar disorder. The compound is also a key reactant in the synthesis of hydroxyethylene-based HIV-1 protease inhibitors containing a heterocyclic core, contributing to antiviral drug development.

In medicinal chemistry and chemical biology research, 4-aminoisoxazole serves as a privileged scaffold for constructing focused libraries of bioactive molecules. The isoxazole ring is a bioisostere of both benzene and pyridine, and its incorporation into drug candidates often enhances metabolic stability, lipophilicity, and target binding affinity. The primary amino group at the 4-position provides a reactive handle for amide coupling, reductive amination, sulfonylation, and urea formation, enabling the construction of diverse molecular architectures. The compound has been found to be active against tumor cell lines, supporting its utility in oncology drug discovery. Recent studies have also identified aminoisoxazole derivatives as potent inhibitors of tryptophan 2,3-dioxygenase 2 (TDO2), an enzyme target for cancer immunotherapy.

In agrochemical development, 4-aminoisoxazole and its derivatives have been investigated for anticonvulsant and pesticidal activities. The isoxazole scaffold is a common structural motif in modern crop protection agents, and 4-aminoisoxazole serves as a key intermediate for introducing the isoxazole-4-amino pharmacophore into agrochemical active ingredients. The compound’s derivatives are also explored for their potential in developing novel fungicides and herbicides.

In specialty chemical synthesis and materials science, 4-aminoisoxazole is used as a precursor for the synthesis of functional materials, including fluorinated compounds, coordination complexes, and specialty polymers. The compound’s ability to coordinate with metal ions through both the ring nitrogen and the amino group makes it valuable for developing metal-organic frameworks (MOFs) and catalytic materials.

Key Properties and Reactivity Profile

4-Aminoisoxazole (CAS# 108511-97-3) is a heterocyclic primary amine whose value derives from the orthogonal reactivity of its amino group and isoxazole ring.

Key physicochemical parameters include:

• Molecular Formula: C₃H₄N₂O
• Molecular Weight: 84.08 g/mol
• CAS Number: 108511-97-3 (free base); 108511-98-4 (hydrochloride)
• MDL Number: MFCD08234629
• Synonyms: Isoxazol-4-amine; 1,2-Oxazol-4-amine; Isoxazole-4-amine; 4-Isoxazolamine
• IUPAC Name: 1,2-oxazol-4-amine
• SMILES: NC1=CON=C1; NC1C=NO[C]=1
• InChIKey: CVCYZCBJCQXUCN-UHFFFAOYSA-N
• Appearance: Brown solid (hydrochloride); free base available as solid
• Purity: ≥95% (free base); ≥98% (hydrochloride)
• Melting Point: 130–135°C with decomposition (free base)
• Boiling Point: 95.714°C (predicted)
• Storage: Cool, dark place, inert atmosphere, protect from moisture
• GHS Classification: Warning; H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation)
• Hazard Statement(s): H315, H319, H335
• Precautionary Statement(s): P261, P305+P351+P338

The compound’s reactivity is defined by its two orthogonal handles: the primary amino group at C4 enables diazotization, acylation, sulfonylation, reductive amination, and Schiff base formation, while the isoxazole ring provides an electron-rich heteroaromatic scaffold that engages in hydrogen bonding, π-stacking, and metal coordination. The 4-position of the isoxazole ring is a privileged site for medicinal chemistry modifications, as substituents at this position can modulate the electronic properties and biological activity of the resulting molecules. The compound has two primary acidic protons that can be abstracted by a strong base, enabling further functionalization.

Manufacturing and Synthesis

The synthesis of 4-aminoisoxazole has been optimized to achieve high yields and purity under mild conditions. A patented mild synthesis method (CN112457268A) comprises three key steps: (1) isoxazole is dissolved in a mixed solvent of acetic acid and acetic anhydride, and ammonium nitrate is added in batches under temperature control; (2) the reaction mixture is poured into ice water, extracted with ethyl acetate, and concentrated to obtain 4-nitroisoxazole; (3) ethanol, concentrated hydrochloric acid, and 5% palladium carbon are added to 4-nitroisoxazole, heated and pressurized to react completely, cooled to 0–10°C, filtered, and washed with glacial ethanol to obtain 4-aminoisoxazole hydrochloride. This method performs the nitration reaction under mild conditions, has low risk, is suitable for industrial production, and significantly improves the yield.

Alternative synthetic routes include the Thorpe cyclization of α-(acylmethoxyimino)nitriles in the presence of lithium hydroxide to yield 5-acyl-4-aminoisoxazoles, and the cyclization of O-(β-oxoalkyl)-substituted α-hydroxyimino nitriles to produce 3,5-disubstituted 4-aminoisoxazoles. The purity of target 4-aminoisoxazoles can be substantially increased by treating O-alkylated oximes with LiClO₄ before cyclization.

Major Market Participants

The global supply system for 4-aminoisoxazole (CAS# 108511-97-3) features a pattern of “specialized pharmaceutical intermediate manufacturers, multinational research chemical distributors, and Chinese producers serving distinct market segments.” As a specialized heterocyclic building block rather than a bulk commodity, the market is characterized by a moderate number of suppliers catering to pharmaceutical R&D, medicinal chemistry, and academic research.

In the global research and high-purity segment, key international suppliers include Fluorochem (UK), offering 4-aminoisoxazole under product code F076275 with 100 mg packaging at £38.00 and in-stock availability. AK Scientific (AKSci) offers the compound at 95% purity under product code X8883, with all products stocked and shipped from the SF Bay Area, California, USA. Biosynth offers 4-aminoisoxazole (CAS 108511-97-3) with a molecular weight of 84.08 g/mol and minimum 95% purity. Apollo Scientific (UK) offers 4-aminoisoxazole hydrochloride (CAS 108511-98-4) at 98% purity. BOC Sciences offers 4-aminoisoxazole hydrochloride as a versatile intermediate for the synthesis of kinase inhibitors and HIV-1 protease inhibitors. BenchChem provides comprehensive technical documentation for 4-aminoisoxazole hydrochloride, including thermal stability and decomposition profiles, and offers the compound for drug development research. Santa Cruz Biotechnology offers 1,2-oxazol-4-amine (CAS 108511-97-3) under catalog number sc-334198. CymitQuimica (Biosynth brand) offers both 4-aminoisoxazole and its hydrochloride salt with molecular weights of 84.08 g/mol and 120.54 g/mol respectively. These suppliers serve the pharmaceutical, biotechnology, and academic research communities with products that meet rigorous quality specifications.

In the industrial and large-scale production segment, Chinese manufacturers have emerged as significant players in the global supply chain. XinChem is a reliable manufacturer and supplier of high-purity 4-aminoisoxazole from China, offering the compound with stringent quality standards for use in pharmaceutical R&D, medicinal chemistry, and drug discovery applications. XinChem provides the compound as a privileged heterocyclic primary amine building block with comprehensive quality documentation, batch-specific Certificates of Analysis (COA), customizable packaging, and globally compliant REACH, ISO 9001, and GMP-aligned manufacturing. The company emphasizes that 4-aminoisoxazole is a privileged heterocyclic primary amine building block containing a five-membered ring, and its heterocyclic scaffold demonstrates potential interactions with the GABA A receptor, making it a valuable lead for epilepsy, anxiety, and sleep disorder research. Other Chinese suppliers include Bide Pharmatech (毕得医药), offering 4-aminoisoxazole (CAS 108511-97-3) at 97% purity with batch quality inspection reports (NMR, HPLC, GC). MolCore (摩库) offers the compound at NLT 98% purity, compliant with ISO certification systems for global pharmaceutical R&D and quality control requirements. Capot Chemical (科邦特) offers 4-aminoisoxazole with kilogram-scale production and long-term commercial supply support, with custom specifications available. Shanghai Aladdin Biochemical Technology offers 4-aminoisoxazole hydrochloride under catalog number A108511-98-4. Sichuan Weikeqi Biotechnology (四川省维克奇生物科技有限公司) offers the compound at competitive pricing. Bide Pharmatech also offers 4-aminoisoxazole hydrochloride (CAS 108511-98-4) at 95% purity with batch quality inspection reports. Chinese suppliers offer the compound at various purity grades (typically 95–99%) and packaging options—from grams to multi-kilogram quantities—serving both domestic and export markets.

Regional Market Dynamics

The global 4-aminoisoxazole market exhibits distinct regional characteristics, with production concentrated in Asia-Pacific (particularly China) and consumption distributed across North America, Europe, and the Asia-Pacific region, aligned with the pharmaceutical, biotechnology, and academic research industries in these regions.

The Asia-Pacific region has emerged as a significant production hub for 4-aminoisoxazole, with China hosting numerous manufacturers and suppliers including XinChem. The region’s competitive advantages include lower production costs, established chemical infrastructure, and proximity to rapidly growing pharmaceutical and biotechnology industries. Chinese suppliers offer the compound at various purity grades (typically 95–99%) and packaging options, serving both domestic and export markets. The growing pharmaceutical R&D, medicinal chemistry, and drug discovery sectors in China, India, Japan, and South Korea continue to drive regional consumption growth. The compound is classified as a pharmaceutical intermediate and organic synthesis intermediate in the Chinese market, with multiple suppliers offering the product in packaging sizes ranging from grams to kilograms.

North America remains a key market for high-purity and research-grade 4-aminoisoxazole, driven by demand from the pharmaceutical industry, biotechnology companies, and academic research institutions. The United States hosts numerous research organizations, pharmaceutical companies, and contract research organizations that require high-quality heterocyclic building blocks for drug discovery and development. AK Scientific, Santa Cruz Biotechnology, and BOC Sciences serve the North American market with extensive distribution networks. The region’s well-established regulatory framework, including FDA oversight of pharmaceutical manufacturing, supports demand for high-grade research chemicals and pharmaceutical intermediates.

Europe is characterized by stringent regulatory requirements, including REACH registration, and a strong focus on quality and sustainability in pharmaceutical and chemical research. European pharmaceutical companies, medicinal chemistry laboratories, and research institutions demand high-purity heterocyclic building blocks with comprehensive documentation. Fluorochem (UK), Apollo Scientific (UK), and Biosynth serve the European market with in-stock availability. The region’s strong pharmaceutical and biotechnology sectors support steady demand for high-quality isoxazole derivatives.

Japan represents a specialized market where 4-aminoisoxazole is supplied for pharmaceutical research, medicinal chemistry, and drug discovery applications.

Regulatory and Safety Considerations

As a heterocyclic primary amine and pharmaceutical intermediate, 4-aminoisoxazole (CAS# 108511-97-3) is subject to regulatory oversight in major global economies. Compliance with relevant regulations is essential for market access and trade.

GHS classification and handling: 4-Aminoisoxazole is classified with the signal word ”Warning”. Hazard statements include H315 (Causes skin irritation), H319 (Causes serious eye irritation), and H335 (May cause respiratory irritation). Precautionary statements include P261 (Avoid breathing dust/fume/gas/mist/vapours/spray), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do; continue rinsing). The compound should be stored in a cool, dark place under inert atmosphere, protected from moisture. Personal protective equipment including lab gloves, safety glasses, and a lab coat should be worn during handling, and operations should be conducted in a well-ventilated environment.

Storage and stability: 4-Aminoisoxazole should be stored in a cool, dark place under inert atmosphere, protected from moisture. The compound has a melting point of 130–135°C with decomposition for the free base. The hydrochloride salt form (CAS 108511-98-4) is a brown solid that is generally more stable and easier to handle than the free base.

Regulatory compliance: In the European Union, the compound must comply with REACH registration requirements for import and use. Manufacturers and suppliers must provide comprehensive Safety Data Sheets (SDS) and maintain appropriate documentation. In the United States, 4-aminoisoxazole is intended for research and development use only and is not intended for therapeutic, food, cosmetic, or consumer applications unless explicitly stated otherwise. For pharmaceutical intermediate applications, manufacturers must comply with relevant FDA regulations and quality standards. The compound is not a controlled substance.

Transport information: 4-Aminoisoxazole is not classified as hazardous material for DOT/IATA transport purposes under standard conditions. Proper packaging, labeling, and documentation are nevertheless required for international shipping. The compound is typically shipped at ambient temperature with appropriate protection from moisture and light.

Future Outlook

The market outlook for 4-aminoisoxazole is positive, supported by several key growth drivers across its major application segments. While the compound remains a relatively specialized heterocyclic building block, its privileged isoxazole scaffold and essential role in GABA A receptor modulator, GSK3 inhibitor, and HIV-1 protease inhibitor development position it for steady growth in the coming years.

Key growth drivers include:

1. Expansion of GABA A receptor modulator therapeutics: The growing global demand for treatments for epilepsy, anxiety, and sleep disorders drives demand for 4-aminoisoxazole as a key building block for GABA A receptor modulators. The compound’s heterocyclic scaffold demonstrates potential interactions with the GABA A receptor, making it a valuable lead for neurological disorder research.
2. Growth in GSK3 inhibitor development: The increasing interest in GSK3 inhibitors for diabetes, Alzheimer’s disease, and bipolar disorder drives demand for 4-aminoisoxazole as a validated starting material for the preparation of glycogen synthase kinase 3 (GSK3) inhibitors. The compound enables robust synthesis of GSK3 inhibitors with Ki values in the nanomolar to picomolar range.
3. Expansion of antiviral drug development: The continued global demand for HIV-1 protease inhibitors drives consumption of 4-aminoisoxazole as a key reactant in the synthesis of hydroxyethylene-based HIV-1 protease inhibitors containing a heterocyclic core.
4. Growth in oncology drug discovery: The compound’s activity against tumor cell lines and its role in the synthesis of TDO2 inhibitors support demand from oncology drug discovery programs targeting cancer immunotherapy.
5. Increasing focus on privileged heterocyclic scaffolds: The growing recognition of the isoxazole ring as a privileged scaffold in medicinal chemistry drives demand for 4-aminoisoxazole as a versatile building block for drug discovery programs targeting diverse therapeutic areas.

Challenges and considerations:

• Handling requirements: The compound’s classification as an irritant (H315, H319, H335) requires appropriate safety measures during handling and storage.
• Limited scale: As a specialized heterocyclic building block, the market for 4-aminoisoxazole is smaller than that of commodity chemicals.
• Competition from alternative building blocks: The market faces competition from other aminoisoxazole positional isomers (3-aminoisoxazole, 5-aminoisoxazole) and alternative heterocyclic primary amines.
• Regulatory compliance: Increasingly stringent pharmaceutical and chemical regulations may require ongoing investment in quality systems and documentation.

To succeed in this evolving market landscape, suppliers must focus on product quality (particularly purity and batch-to-batch consistency), supply chain reliability, regulatory compliance, and responsive customer service. Companies that can offer high-purity products, flexible packaging options, and technical support for pharmaceutical, medicinal chemistry, and drug discovery applications will be well-positioned to capture growing demand.

Shanghai XinChem Co., Ltd. (XinChem)

As a world-leading supplier of organic chemicals and heterocyclic building blocks, Shanghai XinChem Co., Ltd. (XinChem) is dedicated to meeting the innovative needs of the pharmaceutical, biotechnology, and fine chemical industries. Leveraging extensive experience and advanced manufacturing capabilities, XinChem provides high-quality 4-Aminoisoxazole (CAS# 108511-97-3) to customers worldwide. As a trusted manufacturer and supplier based in China, XinChem combines competitive pricing, reliable supply, and exceptional service to establish itself as a preferred partner for pharmaceutical companies, medicinal chemistry researchers, and drug discovery institutions seeking this versatile privileged heterocyclic primary amine building block.

1. Technical Advantages

Advanced Synthesis and Purification Processes
XinChem utilizes state-of-the-art manufacturing facilities and rigorous quality control measures to ensure the purity, consistency, and safety of its 4-aminoisoxazole products. The production process incorporates established synthetic routes—including the mild nitration of isoxazole followed by catalytic hydrogenation to the corresponding amine, and alternative cyclization methods from α-(acylmethoxyimino)nitriles—enabling the delivery of products with purity ≥95% (free base) and ≥98% (hydrochloride salt) to meet diverse application requirements. Strict process control ensures consistent product quality, minimal impurities, and batch-to-batch reproducibility, providing customers with reliable performance in GABA A receptor modulator synthesis, GSK3 inhibitor development, and HIV-1 protease inhibitor manufacturing.

Full-Chain Quality Control
The production process strictly adheres to international quality standards, with comprehensive quality control covering raw material sourcing, in-process monitoring, and finished product testing. Each batch is accompanied by a detailed Certificate of Analysis (COA) documenting physical and chemical properties, purity data (HPLC/GC), melting point (130–135°C for free base), and impurity profiles. XinChem offers batch-specific COA, customizable packaging, and globally compliant REACH, ISO 9001, and GMP-aligned manufacturing.

2. Product Advantages

High Purity and Consistent Quality
XinChem offers 4-aminoisoxazole with purity ≥95% (free base) and ≥98% (hydrochloride salt), ensuring optimal performance in pharmaceutical R&D, medicinal chemistry, and drug discovery applications. The product’s high purity minimizes the risk of unwanted side reactions and impurities, making it suitable for demanding applications in neurological disorder research, kinase inhibitor development, and antiviral drug development. The compound is supplied as a brown solid (hydrochloride) or free base with consistent appearance and defined melting point specifications.

Comprehensive Specifications
Key specifications include:

• Molecular Formula: C₃H₄N₂O (free base); C₃H₅ClN₂O (hydrochloride)
• Molecular Weight: 84.08 g/mol (free base); 120.54 g/mol (hydrochloride)
• CAS Number: 108511-97-3 (free base); 108511-98-4 (hydrochloride)
• Synonyms: Isoxazol-4-amine; 1,2-Oxazol-4-amine; Isoxazole-4-amine; 4-Isoxazolamine
• MDL Number: MFCD08234629
• Appearance: Brown solid (hydrochloride); free base available as solid
• Purity: ≥95% (free base) / ≥98% (hydrochloride)
• Melting Point: 130–135°C with decomposition (free base)
• Boiling Point: 95.714°C (predicted)
• Storage: Cool, dark place, inert atmosphere, protect from moisture
• GHS Classification: Warning; H315, H319, H335
• Precautionary Statement(s): P261, P305+P351+P338

Flexible Packaging Solutions
XinChem provides a range of packaging options to accommodate diverse customer needs, from laboratory-scale quantities (100 mg, 250 mg, 1 g, 5 g) to industrial-scale packaging (10 g, 25 g, 100 g, 500 g, 1 kg) and bulk shipments. Customized packaging solutions are available upon request, ensuring safe handling, storage, and transportation with appropriate protection from moisture and light.

3. Application Fields

As a privileged heterocyclic primary amine building block, 4-Aminoisoxazole (CAS# 108511-97-3) exhibits wide application value across multiple industries:

Pharmaceutical R&D and Drug Discovery:

• Key building block for GABA A receptor modulators for epilepsy, anxiety, and sleep disorder research
• Validated starting material for glycogen synthase kinase 3 (GSK3) inhibitors (Ki 0.001–10,000 nM range)
• Key reactant in the synthesis of hydroxyethylene-based HIV-1 protease inhibitors
• Intermediate for kinase inhibitors and other bioactive molecules
• Precursor for tryptophan 2,3-dioxygenase 2 (TDO2) inhibitors for cancer immunotherapy
• Building block for oncology drug discovery programs

Medicinal Chemistry and Chemical Biology Research:

• Privileged scaffold for constructing focused libraries of bioactive molecules
• Bioisostere of benzene and pyridine for metabolic stability enhancement
• Reactive handle for amide coupling, reductive amination, sulfonylation, and urea formation
• Tool for studying structure-activity relationships in drug discovery

Agrochemical Development:

• Intermediate for anticonvulsant and pesticidal agents
• Building block for isoxazole-containing crop protection agents

Specialty Chemical Synthesis and Materials Science:

• Precursor for functional materials, fluorinated compounds, and coordination complexes
• Building block for metal-organic frameworks (MOFs) and catalytic materials

4. Service Support

Technical Expertise and Customized Solutions
XinChem’s team of experienced chemists and application engineers provides full technical support throughout the customer journey—from product selection and specification development to application guidance and troubleshooting. Whether customers require optimization of synthetic routes, guidance on derivatization strategies for GABA A receptor modulators, or assistance with regulatory documentation, XinChem’s technical experts are ready to help. Custom synthesis and contract manufacturing with flexible scaling from R&D to commercial quantities are available upon request.

Global Logistics and Reliable Supply
With established supply chains serving markets across Europe, North America, Asia-Pacific, and beyond, XinChem ensures timely delivery and consistent product availability. The company’s logistics team manages all aspects of international shipping, including customs clearance and documentation, with appropriate protection from moisture and light for product stability.

Regulatory Support
XinChem provides comprehensive documentation to support regulatory compliance, including Safety Data Sheets (SDS), Certificates of Analysis (COA), and other required certificates. The company stays current with evolving regulatory requirements in major markets, including REACH, TSCA, and other regional regulations, helping customers navigate the complexities of global trade.

5. Reasons to Choose XinChem

• Professionalism: Extensive experience and deep expertise in heterocyclic building block synthesis and supply.
• Quality: Rigorous quality control, high purity (≥95% to ≥98%), and adherence to international standards.
• Reliability: Stable supply, competitive pricing, and timely delivery.
• Flexibility: Customized solutions to meet diverse customer needs, including custom synthesis and packaging.
• Service: Responsive technical support and comprehensive documentation including batch-specific COA.

Contact us today to start your partnership with XinChem!

Website: www.xinchem.com

Email: sales1@xinchem.com

WhatsApp: +86 18049800532